martha schwartz, LLC

147 sherman street
suite 200
cambridge, massachusetts 02140

NYS Entity Status
ACTIVE

NYS Filing Date
AUGUST 21, 2013

NYS DOS ID#
4448524

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2013 - MARTHA SCHWARTZ, LLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • When Bad Drinks Go Good
    By ROBERT SIMONSON - Friday Aug 4, 2017

    The Long Island iced tea, the Midori sour, the Blue Hawaii: Fussy bartenders are upgrading these decidedly down-market cocktails.

    Source: NYT > Home Page
  • Op-Ed Contributor: Yard Rage: The Rand Paul Assault
    By BOB MORRIS - Saturday Nov 11, 2017

    What could it have been about? Oh, any number of things, a highly scientific analysis of feuding neighbors through history suggests.

    Source: NYT > Home Page
  • The Culture Caught Up With Spike Lee — Now What?
    By THOMAS CHATTERTON WILLIAMS - Tuesday Nov 21, 2017

    After more than three decades as a provocateur, the filmmaker has returned to the movie that made him famous.

    Source: NYT > Home Page
  • Women of Sex Tech, Unite
    By ANNA NORTH - Friday Aug 18, 2017

    New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.

    Source: NYT > Home Page
  • The Top 10 Moments of New York Fashion Week
    By THE NEW YORK TIMES - Friday Sep 15, 2017

    Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.

    Source: NYT > Home Page
  • Ultragenyx Makes Competing Bid for Gene Therapy Biotech Dimension Tx
    By Frank Vinluan - Monday Sep 18, 2017

    A bidding war has erupted for gene therapy developer Dimension Therapeutics. Ultragenyx Pharmaceutical (NASDAQ: RARE) announced Monday that it is ready to pay $5.50 per share in cash, or approximately $136 million, to acquire Cambridge, MA-based Dimension (NASDAQ: DMTX). The non-binding proposal from Novato, CA-based Ultragenyx is a 358 percent premium over Dimension’s stock price […]

    Source: Xconomy VC, Deals, & Startups Feed